Rashmi Sharma

Our research group is focused on developing novel therapeutic strategies to address the critical challenge of antimicrobial resistance, with an emphasis on drug discovery for infectious diseases. We focus on identifying new drug targets and treatment approaches specifically against Mycobacterium tuberculosis and ESKAPE pathogens—major contributors to drug-resistant and hospital-acquired infections. By integrating knowledge of bacterial metabolism, resistance mechanisms, and host-pathogen interactions, we aim to advance innovative therapies that support global health and combat the rising threat of resistant infections.

h index : 15, 

i10 index : 19

• Antimicrobial Resistance (AMR)
• Drug Discovery
• Mycobacterium tuberculosis
• ESKAPE Pathogens
• Host-Pathogen Interactions
• Bacterial Metabolism

• Awarded the prestigious Har Gobind Khorana-Innovative Young Biotechnologist Fellowship (IYBF)-2024
• Awarded with 'The French Institute in India (IFI) and the Embassy of France in India Sponsored Research Visit', 2022
• Awarded DBT-Research Associate, 2020
• Awarded SERB Indo-U.S. Postdoctoral Fellowship, 2017 to undertake research at Infectious Disease Research Institute, Seattle, U.S.
• Awarded Nehru Fulbright Postdoctoral Fellowship, 2018.
• Qualified Graduate aptitude test in Engineering (GATE) in Life sciences, 2010 and 2011

• ICMR investigator-initiated project (Principal Investigator), Budget: 1.4 Cr, Status: ongoing, 2025-2028, Title: lead optimization of identified coumarin and indazoline anti-TB scaffolds targeting drug-resistant and latent tuberculosis
• DBT-Innovative Young Biotechnologist Fellowship (Principal Investigator), Budget: 60 lakh, Status: Ongoing, 2025-2028, Title: Chemical modulation of autophagy signalling pathways to identify novel Host directed therapeutics against drug resistant tuberculosis
• CSIR- Research and Development Seed grant (Principal Investigator), Budget: 15.2 lakh, Status: Ongoing, 2024-2026, Title : Hit to lead identification of pyrimidines as anti-TB Scaffolds Targeting Drug-Resistant and Latent Tuberculosis
• AYUSH-CCRAS (Principal Investigator), Budget: 18 lakh, Status: Ongoing, 2023-2026, Title: Pre-clinical development of Guduchi (Tinospora cordifolia (Thunb) Miers) stem through AYUSH route for adjunct therapy in tuberculosis to reduce anti-tubercular treatment (ATT) induced hepatotoxicity
• CSIR Mission Project (Co-Principal Investigator), Budget: 3.5 Cr, Status: Ongoing, 2024-2027, Title : A comprehensive approach to address Antimicrobial Resistance (AMR) (CSIR-MMP-075202)
• DST SERB startup research grant (Principal Investigator), budget: 30 lakh, status: Completed, 2022-2024, Title: Chemical modulation of bacterial ATP synthase to identify novel chemical scaffolds targeting active and latent Mycobacterium tuberculosis

• Anjali Negi, Summaya Perveen, Harpreet Kour, Parvinder Pal Singh, Rashmi Sharma*. Keeping up with the Q’s: Mechanistic Insights and Validation of Quinoline and Quinazoline scaffolds as potent drugs against Tuberculosis . ACS Journal of Medicinal Chemistry (2025)
• Anjali Gangwar, Sapna Saini, and Rashmi Sharma* Galectins as Drivers of Host-Pathogen Dynamics in Mycobacterium tuberculosis Infection. ACS Infectious Diseases (2025)
• Sapna Saini, Sunny Pal, and Rashmi Sharma*. Decoding the Role of Antimicrobial Peptides in the Fight against Mycobacterium tuberculosis. ACS Infectious Diseases (2025), 11, 2, 350–365
• Summaya Perveen, Sunny Pal & Rashmi Sharma*. Breaking the energy chain: importance of ATP synthase in Mycobacterium tuberculosis and its potential as a drug target. RSC Medicinal Chemistry (2025), 16, 1476-1498
• Sapna Saini, G. Lakshma Reddy, Anjali Gangwar, Harpreet Kour, Gajanan G. Nadre, Ramajayan Pandian, Sunny Pal, Utpal Nandi, Rashmi Sharma*, and Sanghapal D. Sawant*. Discovery and Biological Evaluation of Nitrofuranyl-Pyrazolopyrimidine Hybrid Conjugates as Potent Antimicrobial Agents Targeting Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus. RSC Medicinal Chemistry, (2025), 16, 1304-1328
• Puneet Kumar, Sapna Saini, Anjali Gangwar, Rashmi Sharma*, and Jasha Momo H. Anal*. Antibacterial activity of structurally diverse natural prenylated isobavachalcone derivatives. RSC advances, (2024), 14 (45) 32771-32785
• Summaya Perveen, Anjali Negi, Sapna Saini, Anjali Gangwar, & Rashmi Sharma*. Identification of Chemical Scaffolds Targeting Drug-Resistant and Latent Mycobacterium tuberculosis through High-Throughput Whole-Cell Screening. ACS Infectious Diseases, (2024), 10(2), 513–526.
• Anjali Negi, Summaya Perveen, Ria Gupta, Parvinder Pal Singh, & Rashmi Sharma*. Unraveling Dilemmas and Lacunae in the Escalating Drug Resistance of Mycobacterium tuberculosis to Bedaquiline, Delamanid, and Pretomanid. Journal of Medicinal Chemistry, (2024): 67(4), 2264-2286.
• Anjali Negi, & Rashmi Sharma*. The significance of persisters in tuberculosis drug discovery: Exploring the potential of targeting the glyoxylate shunt pathway. European Journal of Medicinal Chemistry (2024): 265, 116058.
• Sapna Saini, Anjali Gangwar, and Rashmi Sharma*. Harnessing Host-Pathogen Interactions for Innovative Drug Discovery and Host-Directed Therapeutics to tackle tuberculosis. Microbiological Research (2023): 127466.
• Gourav Paudwal, Rigzin Dolkar, Summaya Perveen, Rashmi Sharma, Parvinder Pal Singh, & Prem N. Gupta. Third generation Solid Dispersion-Based formulation of novel Anti-Tubercular agent exhibited improvement in solubility, dissolution and biological activity. The AAPS Journal (2024): 26(3)
• Srestha Mukherjee, Summaya Perveen, Anjali Negi, and Rashmi Sharma*. Evolution of tuberculosis diagnostics: From molecular strategies to nanodiagnostics. Tuberculosis 140 (2023): 102340.
• Summaya Perveen, Anjali Negi, Varun Gopalakrishnan, Satyajit Panda, Vinay Sharma, and Rashmi Sharma*. COVID-19 diagnostics: Molecular biology to nanomaterials. Clinica Chimica Acta 538 (2023): 139-156.
• Summaya Perveen, Diksha Kumari, Kuljit Singh, Rashmi Sharma*. Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance. European Journal of Medicinal Chemistry (2021): 114066.
• Summaya Perveen, Rashmi Sharma* Screening approaches and therapeutic targets: the two driving wheels of tuberculosis drug discovery. Biochemical Pharmacology (2022): 114906.
• Kumari Diksha, Perveen Summaya, Rashmi Sharma, Kuljit Singh. Advancement in leishmaniasis diagnosis and therapeutics: An update. European Journal of Pharmacology (2021): 174436.
• Prateek Kour, Anul Kumar, Rashmi Sharma, Reena Chib, Inshad Ali Khan, Vijai K Rai. Synthesis of 20amino-4H-chromen-4-ylphosphonates and βphosphonomalonates via tandem Knoevenagel-Phospha-Michael reaction and antimicrobial evaluation of newly synthesized β-phosphonomalonates . Research on Chemical Intermediates 43 (2017): 7319-7329
• Rashmi Sharma, Rani Chitra, Mehra Rukmankesh, Nargotra Amit, Chib Reena, Rajput S. Vikrant, Kumar Sunil, Singh Samsher, Sharma R. Parduman, and Khan A. Inshad. Identification and characterization of novel small molecule inhibitors of the acetyltransferase activity of Escherichia coli N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU). Applied microbiology and biotechnology 100 (2016): 3071-3085.
• Rashmi Sharma, Lambu Rao Mallikharjuna, Jamwal Urmila, Rani Chitra, Chib Reena, Wazir Priya, Mukherjee Debaraj, Chaubey Asha, Khan Ali Inshad. Escherichia coli N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU) inhibitory activity of terreic acid isolated from Aspergillus terreus. Journal of biomolecular screening 21.4 (2016): 342-353.
• Rashmi Sharma, Khan Ali Inshad. Mechanism and Potential Inhibitors of GlmU: A Novel Target for Antimicrobial Drug Discovery. Current Drug Targets (2016)
• Mehra Rukmankesh, Rashmi Sharma, Khan A. Inshad, and Nargotra Amit. Identification and optimization of Escherichia coli GlmU inhibitors: an in silico approach with validation thereof. European journal of medicinal chemistry 92 (2015): 78-90.
• Rani Chitra, Mehra Rukmankesh, Rashmi Sharma, Chib Reena, Wazir Priya, Nargotra Amit, and Khan A. Inshad. High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU. Tuberculosis 95.6 (2015): 664-677.
• Sharma Deepak K., Tripathi K. Anil, Rashmi Sharma, Chib Reena, Rasool ur Reyaz, Hussain Altaf, Singh Baldev, Goswami Anindya, Khan A. Inshad, and Mukherjee Debaraj. A new class of bactericidal agents against S. aureus, MRSA and VRE derived from bisindolylmethane. Medicinal Chemistry Research 23.4 (2014): 1643-1653.
• Suresh Narva, Nagesh Nagendra Hunsur, Janupally Renuka, Rajput Vikrant, Rashmi Sharma, Khan A. Inshad, and Gowri Venkata Kondapalli Sekhar Chandra. Synthesis and evaluation of 1-cyclopropyl-6-fluoro-1, 4-dihydro-4-oxo-7-(4-(2-(4-substitutedpiperazin-1-yl) acetyl) piperazin-1-yl) quinoline-3-carboxylic acid derivatives as anti-tubercular and antibacterial agents.European journal of medicinal chemistry 71 (2014): 324-332.
• Kamal Ahmed, Hussaini Ali Mohammed Syed, Faazil Shaikh, Poornachandra Y., Reddy Narender G., Kumar Ganesh C., Rajput Singh Vikrant, Rani Chitra Rashmi Sharma, Khan Ali Inshad , Babu Jagadeesh. N. Anti-tubercular agents. Part 8: synthesis, antibacterial and antitubercular activity of 5-nitrofuran based 1, 2, 3-triazoles. Bioorganic & medicinal chemistry letters 23.24 (2013): 6842-6846.
• Singh Baljinder, Rajinder Parshad, R. K. Khajuria, Santosh K. Guru, Anup S. Pathania, Rashmi Sharma, Reena Chib Chib Reena, Aravinda Subrayashastry, Gupta,K. Vivek , Khan A. Inshad , Bhushan Shashi, Bharate B Sandip and Vishwakarma A. Ram. Saccharonol B, a new cytotoxic methylated isocoumarin from Saccharomonospora azurea. Tetrahedron Letters 54.49 (2013): 6695-6699.
• Singh Baljinder, Guru K. Santosh, Rashmi Sharma, Bharate S. Sonali, Khan A. Inshad, Bhushan Shashi, Bharate B. Sandip, and Vishwakarma A. Ram. Synthesis and anti-proliferative activities of new derivatives of embelin. Bioorganic & medicinal chemistry letters 24.20 (2014): 4865-4870.

• N-Substituted-2H-chromene-3-carboxamide derivatives as potent inhibitor of Mycobacterium tuberculosis and process for preparation thereof., Summaya Perveen, Anjali Negi, Atul Chopra, Zabeer Ahmed, Rashmi Sharma, Parvinder Pal Singh, IN202411098131
• Synthesis of '6-methyl-2-nitro-8-phenyl-5,6,7,8-tetrahydroimidazo[1,2-A]pyrimidin-6-ol' and '2-Benzyl-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-B]oxazole' and their derivatives as anti-TB agents.

• Lung Microbiome: Friend or Foe of Mycobacterium tuberculosis., Perveen, Summaya, and Rashmi Sharma., Microbiome in Inflammatory Lung Diseases., Springer Nature, Singapore, 2022, 207-226
• Advances in the synthesis and antimicrobial applications of metal oxide nanostructures, Navpreet Kaur, Rashmi Sharma, V Sharma, Advanced ceramics for versatile interdisciplinary applications: A volume in Elsevier series in advanced ceramic material, 978-0-323-89952-9
• Nanozymes for Bioimaging and Disease Diagnostics., Mehul Mahajan, Summaya Perveen, Rashmi Sharma. Nanozymes in Medicine., Springer Nature, 2023, 72